SI1272195T1 - Use of fulvestrant in the treatment of resistant breast cancer - Google Patents

Use of fulvestrant in the treatment of resistant breast cancer

Info

Publication number
SI1272195T1
SI1272195T1 SI200130435T SI200130435T SI1272195T1 SI 1272195 T1 SI1272195 T1 SI 1272195T1 SI 200130435 T SI200130435 T SI 200130435T SI 200130435 T SI200130435 T SI 200130435T SI 1272195 T1 SI1272195 T1 SI 1272195T1
Authority
SI
Slovenia
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
SI200130435T
Other languages
Slovenian (sl)
Inventor
Beat Thurlimann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0008172.9A external-priority patent/GB0008172D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1272195T1 publication Critical patent/SI1272195T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
SI200130435T 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer SI1272195T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
EP01917289A EP1272195B1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (1)

Publication Number Publication Date
SI1272195T1 true SI1272195T1 (en) 2006-02-28

Family

ID=35034671

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130435T SI1272195T1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Country Status (1)

Country Link
SI (1) SI1272195T1 (en)

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
IL158273A0 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1311262A4 (en) Cancer treatment by combination therapy
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
IL159887A0 (en) Combination therapy for the treatment of cancer
SI1716853T1 (en) Treatment of cancers of the human body using ET743
AU2003212634A8 (en) Compounds useful in the treatment of cancer
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
EE200200479A (en) The use of exemestane in the treatment of breast cancer
EP1420814A4 (en) Compositions and methods for the therapy and diagnosis of breast cancer
PL366066A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
HUP0200825A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
AU9402401A (en) Treatment of cancers
HUP0200717A3 (en) Radioactive cisplatin in the treatment of cancer
AU2096002A (en) Therapeutic treatment
GB0026015D0 (en) Cancer treatment
IL149281A0 (en) Treatment of cancer
SI1272195T1 (en) Use of fulvestrant in the treatment of resistant breast cancer
EP1463511A4 (en) Combination cancer therapy
PL349955A1 (en) Radioactive cisplatin in the treatment of cancer